Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-23-007954
Filing Date
2023-03-15
Accepted
2023-03-15 07:40:51
Documents
6
Period of Report
2023-03-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2022proxystatement1.htm DEF 14A 730895
2 GRAPHIC ajbackgroundpicture.jpg GRAPHIC 10605
3 GRAPHIC chart-ac73c2eb87514029991.jpg GRAPHIC 98874
4 GRAPHIC cumberlandlogoa02a01.jpg GRAPHIC 12534
5 GRAPHIC cumberlandpharmalogoa01.jpg GRAPHIC 37721
6 GRAPHIC xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-23-007954.txt   955888
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 23733299
SIC: 2834 Pharmaceutical Preparations